RATIONALE: We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mechanical hypersensitivity (allodynia) and on nociceptive pain induced by punctate mechanical stimuli in mice. RESULTS: Subcutaneous administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 microg, intraplantar) mechanical hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus). The order of potency of these drugs to induce antiallodynic effects was the order of their affinity for brain sigma-1 (sigma(1)) receptor ([(3)H](+)-pentazocine-labeled). Antiallodynic activity of haloperidol and its metabolites was dose-dependently prevented by the selective sigma(1) receptor agonist PRE-084, but not by naloxone. These results suggest the involvement of sigma(1) receptors, but discard any role of the endogenous opioid system, on the antiallodynic effects. Dopamine receptor antagonism also appears unlikely to be involved in these effects, since the D(2)/D(3) receptor antagonist (-)-sulpiride, which had no affinity for sigma(1) receptors, showed no antiallodynic effect. None of these drugs modified hind-paw withdrawal after a painful (4 g force) punctate mechanical stimulus in noncapsaicin-sensitized animals. As expected, the control drug gabapentin showed antiallodynic but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as negative control, showed neither. CONCLUSION: These results show that haloperidol and its metabolites I and II produce antiallodynic but not antinociceptive effects against punctate mechanical stimuli and suggest that their antiallodynic effect may be due to blockade of sigma(1) receptors but not to dopamine receptor antagonism.
RATIONALE: We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mechanical hypersensitivity (allodynia) and on nociceptive pain induced by punctate mechanical stimuli in mice. RESULTS: Subcutaneous administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 microg, intraplantar) mechanical hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus). The order of potency of these drugs to induce antiallodynic effects was the order of their affinity for brain sigma-1 (sigma(1)) receptor ([(3)H](+)-pentazocine-labeled). Antiallodynic activity of haloperidol and its metabolites was dose-dependently prevented by the selective sigma(1) receptor agonist PRE-084, but not by naloxone. These results suggest the involvement of sigma(1) receptors, but discard any role of the endogenous opioid system, on the antiallodynic effects. Dopamine receptor antagonism also appears unlikely to be involved in these effects, since the D(2)/D(3) receptor antagonist (-)-sulpiride, which had no affinity for sigma(1) receptors, showed no antiallodynic effect. None of these drugs modified hind-paw withdrawal after a painful (4 g force) punctate mechanical stimulus in noncapsaicin-sensitized animals. As expected, the control drug gabapentin showed antiallodynic but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as negative control, showed neither. CONCLUSION: These results show that haloperidol and its metabolites I and II produce antiallodynic but not antinociceptive effects against punctate mechanical stimuli and suggest that their antiallodynic effect may be due to blockade of sigma(1) receptors but not to dopamine receptor antagonism.
Authors: Cruz Miguel Cendán; José Miguel Pujalte; Enrique Portillo-Salido; Lluís Montoliu; José M Baeyens Journal: Eur J Pharmacol Date: 2005-03-21 Impact factor: 4.432
Authors: S K Joshi; G Hernandez; J P Mikusa; C Z Zhu; C Zhong; A Salyers; C T Wismer; P Chandran; M W Decker; P Honore Journal: Neuroscience Date: 2006-09-08 Impact factor: 3.590
Authors: Sharon Bingham; Paul J Beswick; Chas Bountra; Terry Brown; Ian B Campbell; Iain P Chessell; Nick Clayton; Sue D Collins; Philip T Davey; Helen Goodland; Norman Gray; Claudine Haslam; Jonathan P Hatcher; A Jacqueline Hunter; Fiona Lucas; Graham Murkitt; Alan Naylor; Elizabeth Pickup; Becky Sargent; Scott G Summerfield; Alexander Stevens; Sharon C Stratton; Joanne Wiseman Journal: J Pharmacol Exp Ther Date: 2004-11-30 Impact factor: 4.030
Authors: Cruz M Cendán; José M Pujalte; Enrique Portillo-Salido; José M Baeyens Journal: Psychopharmacology (Berl) Date: 2005-10-19 Impact factor: 4.530
Authors: Robert W Gear; Janice S Lee; Christine Miaskowski; Newton C Gordon; Steven M Paul; Jon D Levine Journal: J Pain Date: 2006-03 Impact factor: 5.820
Authors: L Romero; D Zamanillo; X Nadal; R Sánchez-Arroyos; I Rivera-Arconada; A Dordal; A Montero; A Muro; A Bura; C Segalés; M Laloya; E Hernández; E Portillo-Salido; M Escriche; X Codony; G Encina; J Burgueño; M Merlos; J M Baeyens; J Giraldo; J A López-García; R Maldonado; C R Plata-Salamán; J M Vela Journal: Br J Pharmacol Date: 2012-08 Impact factor: 8.739
Authors: Miguel A Tejada; Angeles Montilla-García; Shane J Cronin; Domagoj Cikes; Cristina Sánchez-Fernández; Rafael González-Cano; M Carmen Ruiz-Cantero; Josef M Penninger; José M Vela; José M Baeyens; Enrique J Cobos Journal: Proc Natl Acad Sci U S A Date: 2017-07-17 Impact factor: 11.205
Authors: M A Tejada; A Montilla-García; C Sánchez-Fernández; J M Entrena; G Perazzoli; J M Baeyens; E J Cobos Journal: Psychopharmacology (Berl) Date: 2014-03-18 Impact factor: 4.530
Authors: Young Bae Kwon; Young Chan Jeong; Jung Kee Kwon; Ji Seon Son; Kee Won Kim Journal: Korean J Physiol Pharmacol Date: 2009-12-31 Impact factor: 2.016
Authors: Francisco R Nieto; Cruz M Cendán; Francisco J Cañizares; María A Cubero; José M Vela; Eduardo Fernández-Segura; José M Baeyens Journal: Mol Pain Date: 2014-02-11 Impact factor: 3.395